| Similar Articles |
|---|
 |
The Motley Fool
March 12, 2009
Brian Orelli |
2 Suitors Are Better Than 1 Recent drug company acquisitions prove that competition benefits shareholders.   |
BusinessWeek
February 2, 2004
Gene G. Marcial |
CV Investors: Take Heart Lately, CV Therapeutics is bouncing around on rumors of what the Food & Drug Administration might do about Ranexa, CV's angina treatment. One New York fund manager, who asked not to be identified, is buying shares because he expects a takeover bid. |
The Motley Fool
August 7, 2008
Brian Orelli |
The Next Pharma Acquisition The rate of mergers and acquisitions among drugmakers has reached a feverish pace lately, and doesn't show any signs of slowing down anytime soon. Take a look at some likely candidates. |
The Motley Fool
August 1, 2008
Brian Lawler |
Holy Moley, CV Therapeutics! With big successes on the regulatory and financial fronts, CV Therapeutics has had a quarter where everything went right. |
The Motley Fool
September 17, 2008
Brian Lawler |
CV Therapeutics Expands Ranexa's Reach CVT announces that it has finally found a European marketing partner for its angina treatment Ranexa. |
The Motley Fool
April 28, 2008
Brian Lawler |
CV Therapeutics Feels the Love CV Therapeutics announces its second regulatory thumbs-up this month, after its lead drug Ranexa was essentially approved in the European Union. |
The Motley Fool
February 13, 2007
Brian Lawler |
CVT, We Wait for Thee CV Therapeutics' angina treatment could be set for a big boost. But what investors are getting with CVT today is a specialty pharma that is rapidly burning the cash on its balance sheet. |
The Motley Fool
March 7, 2007
Brian Lawler |
A CV Therapeutics Buying Opportunity? Shares of CV Therapeutics tank after reporting mixed results from a pivotal clinical trial for its lead drug. |
The Motley Fool
August 1, 2007
Brian Lawler |
CV Therapeutics' Turnaround Quarter Putting a close to a turnaround second quarter, CV Therapeutics announced its financial results recently. It looks like shareholders are in for some good times. |
The Motley Fool
September 26, 2006
Brian Lawler |
CVT's Looming Date With Destiny A pivotal trial for its lead drug, Ranexa, is nearing completion. Investors, take note. |
The Motley Fool
April 17, 2008
Brian Lawler |
CVT's Copacetic Cash Management Drugmaker CV Therapeutics signs away a little portion of its royalty stream from a recently approved drug, in order to get a lot back. |
The Motley Fool
April 4, 2005
Karl Thiel |
CV Therapeutics' Great Resume With biotechs in the doldrums, this investor goes hunting. |
The Motley Fool
July 10, 2006
Brian Lawler |
CV Therapeutics Gets Greenlighted A final trial could secure full FDA approval for angina drug Ranexa. Investors, take note. |
The Motley Fool
November 7, 2007
Brian Lawler |
Turnaround Time for CVT CV Therapeutics announces in its third-quarter financial results that it plans to have a better 2008; its angina drug shows promise for treating diabetics. Investors, take note. |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
April 14, 2008
Brian Lawler |
A Little Delay Goes Away for CVT CV Therapeutics can move ahead, now that it has won marketing approval for its cardiac stress agent regadenoson. |
The Motley Fool
February 17, 2011
Brian Orelli |
Nice Deal, Now Let's See Some Data AVEO Pharmaceuticals struck a solid partnership with Astellas Pharma and its investors are rewarding the company today. |
The Motley Fool
September 28, 2011
Brian Orelli |
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. |
The Motley Fool
March 29, 2010
Brian Orelli |
5 Drugmakers Producing Cash for You Take greenbacks over earnings any day. |
The Motley Fool
November 1, 2006
Brian Lawler |
Waiting for CVT's Trial Results The biopharm reported third-quarter 2006 earnings that were mostly as expected. Investors are just awaiting the clinical trial results from the company's large phase 3 Merlin study testing its marketed angina drug, Ranexa. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
Chemistry World
March 13, 2009
Sarah Houlton |
Mega mergers sweep pharma industry Just six weeks after Pfizer agreed to buy Wyeth, US pharma companies Merck & Co. and Schering-Plough announced they are to merge. |
The Motley Fool
August 24, 2011
Brian D. Pacampara |
United Therapeutics Shares Got Crushed: What You Need to Know Shares of drugmaker United Therapeutics plunged 17% today after its experimental orally administered lung drug failed in a late-stage clinical trial. |
The Motley Fool
July 20, 2010
Jordan DiPietro |
Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment. |
The Motley Fool
September 15, 2010
Brian Orelli |
Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out. |
The Motley Fool
December 30, 2008
Brian Orelli |
The FDA Needs a Bake Sale Money seems to be at the root of the problem with the FDA right now. It's pretty clear that fees, even though they're up to over $1 million per marketing application, aren't enough to get things done in a timely manner. |
The Motley Fool
April 3, 2009
Brian Orelli |
Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker. |
The Motley Fool
December 31, 2011
David Williamson |
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here? |
The Motley Fool
July 27, 2011
Brian Orelli |
Switching Partners Provides a Big Shot in the Arm Merck loves Cardiome more than Astellas does. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
December 9, 2008
Brian Orelli |
The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point. |
The Motley Fool
March 12, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend by hitting new highs. Take a look at: CV Therapeutics... AutoZone... |
The Motley Fool
June 15, 2011
Brian Orelli |
Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story. |
Pharmaceutical Executive
October 1, 2008
Walter Armstrong |
Global Warming Japanese Pharma is playing a game of catch-up, dropping big cash on biotechs and risky acquisitions. But with patents expiring and sales falling, can they really pay their way to global success? |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
The Motley Fool
June 15, 2005
Brian Gorman |
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. |
The Motley Fool
May 4, 2011
Brian Orelli |
Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down. |
The Motley Fool
March 30, 2005
David Nierengarten |
Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives? |
The Motley Fool
May 28, 2009
Robert Steyer |
Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena. |
The Motley Fool
July 22, 2009
Brian Orelli |
Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
July 28, 2009
Brian Orelli |
I Can't Believe My Company Got Acquired Would you like some cheese with that whining? Investors buy into a biotech company hoping for a 10-bagger after a drug is approved. Instead, they end up getting capped at a double when the biotech gets acquired. |
The Motley Fool
July 26, 2010
Tom Gardner |
A Disaster for Shareholders Two biotechnology stocks not worth the trouble. |
